Clinical trials
Squamous Cell Carcinoma of the Larynx clinical trials
Below are recruiting squamous cell carcinoma of the larynx clinical trials, each written for real people, not researchers. We’re tracking 136 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06725368RecruitingPhase 2
Chemo plus cetuximab after pembrolizumab for head and neck cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Ars-LaquenexyAges 18 years+ - NCT06752798RecruitingPhase 2
Trilaciclib to protect bone marrow after head and neck cancer surgery and chemoradiation
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
Changsha, HunanAges 18–70 - NCT06831149RecruitingPhase 2
Spy imaging to reduce fistulas after throat reconstruction
This study is testing a special imaging tool (SPY system) that helps surgeons see blood flow better during surgery to rebuild the throat. The goal is to reduce the risk of fluid leaks (fistulas) after the operation.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07088211RecruitingPhase 2
New drug combo for first-line head and neck cancer
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07090317RecruitingPhase 2
Testing Two Immunotherapy Drugs for Advanced Head and Neck Cancer
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT02128906RecruitingPhase 2
Radiation plus chemo choices for throat cancer, using a tumor marker
This trial compares two treatment combinations given with radiation for certain cancers of the throat. It also uses a lab test on the tumor (ERCC1) to help choose and study which treatment works better.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07506902Recruiting
Daily adjusted radiation for head and neck cancer
This trial tests a newer, more precise way of giving daily radiation for head and neck cancer. The treatment plan is adjusted each day to better target the tumor and protect healthy tissue.
CopenhagenAges 18 years+ - NCT07573956RecruitingPhase 2/Phase 3
Fast versus standard radiation after head and neck cancer surgery
This trial compares two different radiation schedules after surgery for head and neck cancer. One schedule delivers radiation faster over fewer weeks, while the other uses the standard approach. The study tests whether the faster schedule works just as well while potentially reducing side effects.
Jhajjar, HaryanaAges 18–80 - NCT07580300RecruitingPhase 3
Proton vs. Standard Radiation for Head and Neck Cancer
This trial compares two types of radiation therapy for head and neck cancer: proton therapy (a newer, more targeted approach) versus standard photon therapy (the current common treatment). The goal is to see if protons reduce side effects while treating the cancer just as well.
BergenAges 40–90 - NCT07550972Enrolling by invitationPhase 2
Combination drug treatment before surgery for advanced head and neck cancer
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06287034Recruiting
Free flap surgery after total laryngectomy for laryngeal cancer
This trial tests whether using a free or pedicled tissue flap during total laryngectomy reduces the risk of a pharyngocutaneous fistula (an abnormal opening between the throat and skin). It is for people whose laryngeal cancer came back after radiation or chemoradiation.
Rome, RomeAges 18 years+ - NCT04261192Recruiting
Grow lab models of head and neck cancer to test treatments
This study collects tissue from people with newly diagnosed head and neck squamous cell cancer and grows “mini tumor models” in the lab. The goal is to see how these models respond to new therapies, which may help guide more effective treatment choices in the future.
CaenAges 18 years+ - NCT07405645Recruiting
Focused Ultrasound for Cancer Pain in the Head or Neck
This trial tests a non-invasive focused ultrasound treatment aimed at a specific brain area to reduce severe cancer-related pain in the head, neck, or upper chest. It may help if your pain hasn't responded to standard medications.
Boston, MassachusettsAges 18–85 - NCT06706401RecruitingPhase 3
Lymphocyte-sparing radio-immunotherapy for head and neck cancer
This trial tests a new approach that combines radiation and immunotherapy, while trying to protect your immune cells. It is for people with head and neck cancer that has not spread across the midline of the body and has not been treated yet.
Lyon, FranceAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+
Hear when a new Squamous Cell Carcinoma of the Larynx trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell carcinoma of the larynx?
- Yes. Clin2 currently lists 136 recruiting squamous cell carcinoma of the larynx studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell carcinoma of the larynx trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell carcinoma of the larynx trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.